Frontiers in oncology, 2022-09, Vol.12, p.855794-855794
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
- Ist Teil von
- Frontiers in oncology, 2022-09, Vol.12, p.855794-855794
- Ort / Verlag
- Frontiers Media S.A
- Erscheinungsjahr
- 2022
- Quelle
- EZB Electronic Journals Library
- Beschreibungen/Notizen
- Combination dabrafenib (D) and trametinib (T) is an FDA approved adjuvant therapy for patients with resected stage III BRAF-mutant melanoma. We describe treatment-related toxicities with adjuvant D+T in a real-world population through a retrospective case series. The primary endpoint was development of toxicities. Results Eighteen of the 20 patients (90%) required at least one treatment interruption due to adverse events (AEs), 11 patients (55%) required a dose reduction and 13 (65%) permanently discontinued therapy due to an AE. The nine patients who did not require dose reduction had been initiated on a lower starting dose of dabrafenib. The most common treatment-limiting AEs were recurrent pyrexia and chills (85%) and liver laboratory abnormalities (50%). The median total time on therapy was 148.5 days (range 19-383), 40.7% (range 5.2-100%) of the intended one-year duration. Conclusion Adjuvant treatment of melanoma with combination D+T is associated with treatment-limiting toxicities in the majority of this patient group. Patients should be carefully monitored throughout therapy.